Looking for Gains in Treating Pain
Innovations in spinal cord stimulation bolster moats at Medtronic, Boston Scientific, and Abbott.
We’ve long viewed neuromodulation as a field that offered great promise but faced meaningful challenges to realizing that potential. Thanks to a spurt in innovation in spinal cord stimulation--the largest segment of the neuromodulation market--competitors are poised to make more progress toward addressing some of the areas where SCS has fallen short in the past, providing a catalyst for an acceleration in growth as we look to 2021-25. We like how SCS devices add to a company’s economic moat through intangible assets, including intellectual property, proprietary data gathered by the devices, and the differentiated algorithms generated.
The roughly $2.5 billion global spinal cord stimulation market remains underpenetrated with an estimated 11% of patients receiving the technology. We estimate the market should reach $5 billion by 2030, thanks to the introduction of more efficacious therapy, growing awareness of earlier intervention leading to better outcomes, and greater penetration of the underlying chronic pain patient pool.
Debbie Wang does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.